北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
作者: Luo, Feng Roger1,2; Ding, Jian3; Chen, Helen X.1,4; Liu, Hao5; Fung, Man-Cheong2; Koehler, Maria6; Armand, Jean Pierre7; Jiang, Lei3; Xu, Xiao1,8; Zhang, Ge9; Xu, Li1,9; Qian, Pascal1,5; Yan, Li1,10
关键词: Breakthrough ; clinical trial ; cancer medicine
刊名: CHINESE JOURNAL OF CANCER
发表日期: 2014-12-01
DOI: 10.5732/cjc.014.10246
卷: 33, 期:12, 页:620-624
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: CELL LUNG-CANCER ; GASTRIC-CANCER ; BREAST-CANCER ; INHIBITOR ; PCI-32765 ; IBRUTINIB
英文摘要:

The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the 17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China.

语种: 英语
WOS记录号: WOS:000346228500007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54669
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.US Chinese Anticanc Assoc, Martinez, CA 94553 USA
2.Novartis Pharmaceut China Oncol, Beijing 10004, Peoples R China
3.Pfizer Oncol, New York, NY 10017 USA
4.Inst Gustave Roussy, F-94805 Villejuif, France
5.ACEA Biosci Inc, San Diego, CA 92121 USA
6.Jiangsu Hengrui Med Co Ltd, Shanghai 200122, Peoples R China
7.Janssen Res & Dev LLC, Dept Oncol, Raritan, NJ 08869 USA
8.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
9.NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
10.Peking Univ, Beijing Canc Hosp & Inst, Sch Oncol, Beijing 100142, Peoples R China

Recommended Citation:
Luo, Feng Roger,Ding, Jian,Chen, Helen X.,et al. Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting[J]. CHINESE JOURNAL OF CANCER,2014,33(12):620-624.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Luo, Feng Roger]'s Articles
[Ding, Jian]'s Articles
[Chen, Helen X.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Luo, Feng Roger]‘s Articles
[Ding, Jian]‘s Articles
[Chen, Helen X.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace